Business Wire

lowRISC Collaborates with Industry Leaders to Create OpenTitan

Share

lowRISC C.I.C., the open source silicon and tools collaborative engineering company, today announced that it has partnered with ETH Zürich, Google, G+D Mobile Security, Nuvoton Technology and Western Digital in support of OpenTitan, an open source hardware root of trust (RoT) reference design and integration guidelines that enable chip producers and platform providers to build transparently implemented, high-quality hardware RoT chips tailored for data center servers and other devices.

Security begins with infrastructure, and OpenTitan will help ensure root of trust in hardware, transparently implemented, at the foundation for a multitude of devices such as server motherboards, network cards, routers and IoT. Adopters of this framework can inspect and contribute to OpenTitan’s register-transfer level (RTL) design, firmware, and documentation, helping to build more transparent, trustworthy hardware RoT chips for everyone.

OpenTitan is stewarded by lowRISC, which provides a neutral home for collaborative engineering to develop and maintain open source silicon designs and tools for the long term. As with open source software, open silicon provides a deep level of transparency and therefore auditability, as well as enabling innovation. Shared open infrastructure technology permits focus on product differentiation, with shared costs and substantially reduced overall risk.

The Ibex RISC-V processor core, which was originally developed by ETH Zürich as zero-riscy and contributed to lowRISC earlier this year, forms a key component for OpenTitan. lowRISC is committed to raising the bar for quality in open silicon via a methodical approach that combines the development and use of best practices and coding standards, with rigorous testing and verification.

Key benefits of OpenTitan for chip manufacturers and platform providers include:

  1. Transparent: Adopters can inspect and contribute to OpenTitan’s design, firmware, and documentation, helping to build more transparent, trustworthy hardware RoT chips that benefit everyone.
  2. High-quality: OpenTitan’s goal is to build and maintain a high-quality and logically secure RTL design, firmware, and documentation. The project is staffed by expert engineers focused on rigorous design validation and technical documentation, all based on key learnings from designing Google’s Titan chips.
  3. Flexible: Adopters can increase their total addressable market and reduce costs by using a single platform-agnostic hardware RoT design that can be integrated in data center servers, peripherals, and any other hardware platforms.

“We believe collaboratively developed open source silicon designs provide the flexible, cost effective base needed for future generations of secure hardware products,” said Alex Bradbury, lowRISC CTO. “The lowRISC not-for-profit structure combined with full stack engineering capabilities in-house, enables us to manage high quality projects like OpenTitan, and we look forward to developing this partnership and new ones in the future.”

“At lowRISC, our mission is to establish a vibrant ecosystem around open silicon designs and to help lower the barrier to producing custom chips,” said Gavin Ferris, lowRISC CIC board member. “Creating an ecosystem of like-minded organizations focused on the goal of improving transparency around chips helps increase trust in the overall security of the infrastructure on which software runs. With OpenTitan, enterprise organizations and consumers alike will benefit from services built on a more secure infrastructure that is anchored in transparently implemented OpenTitan chips.”

“Customers are asked to put faith in proprietary hardware RoT chips for their mission-critical systems without the ability to fully understand, inspect and therefore trust them,” said Dominic Rizzo, OpenTitan Lead at Google and lowRISC’s OpenTitan Project Director. “By creating OpenTitan with the broader hardware and academic community, we can leverage the experience and security principles used to create Google’s own Titan chips to make hardware RoT designs more transparent, inspectable, and accessible to the rest of the industry. Security should never be built on opacity.”

Collaboration is fundamental to open silicon and at the core of everything that lowRISC does, bringing to projects a deep understanding of open source licensing, contributor models and community building, and providing a uniquely positioned engineering capability.

About lowRISC

lowRISC C.I.C. is a not-for-profit company that aims to demonstrate, promote and support the use of open-source hardware - bringing the benefits of open-source to the hardware world. We are producing high-quality, security-focused, open, and flexible IP. Our expertise includes the LLVM Compiler, novel hardware security extensions and RISC-V tools, hardware and processor design.

Contact information

Andrew Back
lowRISC
press@lowrisc.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the Future24.1.2020 17:00:00 EETPress release

HighRes Biosolutions and Novo Nordisk A/S today announced that they will collaborate to design a state-of-the-art robotic platform for high-throughput biologics engineering and characterisation. The integration of a multi-system robotics platform with sophisticated software control architecture will enable a digital transformation and accelerated discovery for Novo Nordisk’s peptide and large molecule therapeutics research. “In order to maintain our leadership within biologics engineering we are investing in a fully automated and digital design platform. This investment is linked to our build-up in AI and advanced analytics and demonstrates Novo Nordisk’s commitment as a world leading biologics research company,” said Lars Fogh Iversen, senior vice president, Global Research Technologies, Novo Nordisk. The platform will comprise several highly automated and integrated cells for production, characterisation and functional analysis of thousands of biologic compounds every month. Its scop

Conquest Invests in 5 Greenfield Onshore Wind Parks Totalizing 43MW in the Flanders Region24.1.2020 15:37:00 EETPress release

Conquest, acting through the Conquest Sustainable Infrastructure fund, announced the transaction was closed after an exclusive agreement had been reached with ENGIE Electrabel. Conquest acquires 51% of a portfolio expected to provide 111 GWh per annum of renewable power representing the annual electricity consumption of about 32,000 Belgian homes from early 2021 onwards. The projects benefit from 15 to 20-year green certificates local remuneration schemes, and thus generate yearly secured revenues. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005221/en/ Credit: Electrabel While the energy and digital transitions continue to drive the infrastructure sector, Conquest keeps building its diversified sustainable real asset portfolio in Western European markets. The success lies in years of collaboration and long-lasting partnerships with fellow industry experts who can notably facilitate access to new growth opportunities

Fluence Expands EMEA Footprint with Horticulture Partners in Papenburg, Germany24.1.2020 14:00:00 EETPress release

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, announced today it is expanding its presence in the Emsland region of Germany through partnerships with growers and other horticulture specialists operating out of Papenburg. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005109/en/ Friedrich Schulz’s 5.5 hectare farm—which grows herbs year-round in addition to lettuce, peppers and chives—utilizing VYPR 2p fixtures. (Photo: Business Wire) Given Papenburg’s decades-long history of attracting horticulture experts, Fluence’s innovative lighting solutions for horticulture are a natural fit for the region’s tomato, cucumber, leafy greens and herb growers. Forging connections with Papenburg’s horticultural leaders Elektro Evers, an engineering firm specializing in greenhouse technology, is Fluence’s exclusive systems integrator

HCL Technologies Honors Global Goodwill Champions at the 2020 World Economic Forum in Davos24.1.2020 12:47:00 EETPress release

HCL Technologies (HCL), a leading global technology company, today presented its Wave Maker Awards 2020, commemorating global goodwill champions from around the world. The award ceremony, which was held at the HCL Pavilion in Davos, celebrated organizations and individuals passionately committed to such noble causes as diversity & inclusion, education & community upliftment, environment & sustainability, and technology for change. Special guest at the awards was Australian cricket legend Glenn McGrath, who is also founder of the McGrath Foundation, which provides support for Australian women diagnosed with breast cancer and their families. The award recipients were; Lois Auta, Founder and Executive Director of Cedar Seed Foundation, which supports persons with disabilities to participate in all aspects of life; Chido Govera, Founder and Director of The Future of Hope Foundation (TFoHF), which supports marginal and vulnerable members of society through entrepreneurial and self-developme

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria24.1.2020 09:00:00 EETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), as well as the ongoing Phase II (PVO-1A-202/204) extension studies. In both the Phase III and Phase II extension studies, palovarotene is dosed both chronically (daily) and episodically (during flare-ups). The decision to pause dosing patients in the trial is based on results of a futility analysis reviewed by the Independent Data Monitoring Committee (IDMC) as part of the prespecified interim analysis. The results of a futility analysis indicated that the Phase III FOP trial was unlikely to meet its primary efficacy endpoint (annualized change in new HO volume as compared with Natural History Studyi) upon completion. Despite the results of the prespecified interim analysis, signals of encouraging therapeutic activity w

Amazentis Announces the Launch of Timeline™ Cellular Nutrition at the World Economic Forum in Davos23.1.2020 23:56:00 EETPress release

Amazentis announces the debut of Timeline, a next generation nutrition product designed to promote healthy aging, as part of the Swiss Food & Nutrition Valley in the House of Switzerland at the World Economic Forum in Davos, Switzerland. Given the increase in the aging population globally -- according to a 2019 Deutsche Bank study, there are more people on Earth older than sixty five than younger than five for the first time -- it is imperative for consumers to take proactive measures to maintain a high quality of life, for as long as they live. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005820/en/ (Photo: Business Wire) Timeline contains the proprietary nutrient Mitopure™, a highly pure form of Urolithin A. After a decade of rigorous research by leading scientists around the world, Mitopure has been shown to help counter age-associated cellular and muscular decline by revitalizing the mitochondria, the powerplants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom